Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Co-Chairs' Remarks
Preliminary Results of VISTA: A Phase 3 Study of Vicinium in Subjects with High Grade Non-Muscle Invasive Bladder Cancer (NMIBC)
Vicinium, an anti-EpCAM scFv/Pseudomonas Exotoxin A fusion protein, is in development for the local-regional treatment of EpCAM over expressing carcinomas. A registrational phase 3 study of Vicinium for the treatment of NMIBC recently completed enrollment and preliminary 3 month efficacy and safety data will be discussed.
Chairman's Remarks